The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs
- PMID: 23318502
- DOI: 10.1016/j.regpep.2012.12.012
The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs
Abstract
The most striking sequence difference between glucagon-like peptide-1 (GLP-1)(2) and the longer-acting GLP-1 receptor agonist, exendin-4 (Ex-4),(3) is the nine-amino acid COOH-terminal extension of Ex-4. We investigated the contribution of this extension to the survival time of Ex-4. We assessed the overall metabolism of GLP-1, Ex-4, a COOH-terminally extended GLP-1 peptide (GLP-1+Ex(31-39); GLP-Ex),(4) and a COOH-terminally truncated exendin peptide (Ex(1-30)) in anaesthetized, catheterized pigs, with focus on the extraction across the kidneys and a peripheral tissue (a hindleg, representing muscle, adipose- and connective tissue). Peptide analysis was carried out with assays against the mid-region of the peptides, whereby the role of dipeptidyl peptidase-4 (DPP-4)(5) mediated NH(2)-terminal degradation could be disregarded. The half-life of GLP-1 was significantly increased when the COOH-terminal extension of Ex-4 was added (GLP-1 4.8±3.3min; GLP-Ex 19.5±3.3min). In contrast, there was no effect of truncating Ex-4 (Ex-4 32.4±4.1min; Ex(1-30) 28.4±1.7min). Ex-4 and Ex(1-30) were cleared solely by the kidneys at rates corresponding to the glomerular filtration rate (GFR),(6) while GLP-1 and GLP-Ex were cleared by both the kidneys and peripheral tissues. Both extraction rates were, however, significantly reduced with GLP-Ex compared to GLP-1. The renal clearance rate of GLP-1 greatly exceeded GFR, while GLP-Ex was cleared at a rate resembling GFR. In conclusion, the COOH-terminal extension of Ex-4 contributes minimally to the increased survival time of Ex-4, while addition of this sequence to GLP-1 significantly reduces its clearance.
Copyright © 2013 Elsevier B.V. All rights reserved.
Similar articles
-
Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs.Diabetologia. 2006 Apr;49(4):706-12. doi: 10.1007/s00125-005-0128-9. Epub 2006 Jan 31. Diabetologia. 2006. PMID: 16447056
-
Functional association of the N-terminal residues with the central region in glucagon-related peptides.J Pept Sci. 2011 Oct;17(10):659-66. doi: 10.1002/psc.1385. Epub 2011 Jun 10. J Pept Sci. 2011. PMID: 21661079
-
Biological activity of AC3174, a peptide analog of exendin-4.Regul Pept. 2007 Jun 7;141(1-3):113-9. doi: 10.1016/j.regpep.2006.12.021. Epub 2007 Jan 11. Regul Pept. 2007. PMID: 17292977
-
[Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].MMW Fortschr Med. 2010 Jan 14;151 Suppl 4:173-8. MMW Fortschr Med. 2010. PMID: 21595145 Review. German. No abstract available.
-
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. J Am Pharm Assoc (2003). 2009. PMID: 19801361 Review.
Cited by
-
A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats.PLoS One. 2016 May 2;11(5):e0154727. doi: 10.1371/journal.pone.0154727. eCollection 2016. PLoS One. 2016. PMID: 27136422 Free PMC article.
-
A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.Diabetologia. 2014 Sep;57(9):1927-36. doi: 10.1007/s00125-014-3296-7. Epub 2014 Jun 25. Diabetologia. 2014. PMID: 24962667
-
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?J Endocrinol. 2024 Jul 15;262(2):e230339. doi: 10.1530/JOE-23-0339. Print 2024 Aug 1. J Endocrinol. 2024. PMID: 38861364 Free PMC article. Review.
-
Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP.Drug Des Devel Ther. 2022 May 25;16:1547-1559. doi: 10.2147/DDDT.S358989. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35651477 Free PMC article. Review.
-
Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences.Pharmaceuticals (Basel). 2022 Dec 31;16(1):61. doi: 10.3390/ph16010061. Pharmaceuticals (Basel). 2022. PMID: 36678558 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical